392 related articles for article (PubMed ID: 16522525)
1. Regulation of endocrine-disrupting chemicals: critical overview and deficiencies in toxicology and risk assessment for human health.
Harvey PW; Everett DJ
Best Pract Res Clin Endocrinol Metab; 2006 Mar; 20(1):145-65. PubMed ID: 16522525
[TBL] [Abstract][Full Text] [Related]
2. Endocrine disrupters and human health: could oestrogenic chemicals in body care cosmetics adversely affect breast cancer incidence in women?
Harvey PW; Darbre P
J Appl Toxicol; 2004; 24(3):167-76. PubMed ID: 15211609
[TBL] [Abstract][Full Text] [Related]
3. Health risk assessment procedures for endocrine disrupting compounds within different regulatory frameworks in the European Union.
Beronius A; Rudén C; Hanberg A; Håkansson H
Regul Toxicol Pharmacol; 2009 Nov; 55(2):111-22. PubMed ID: 19500631
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment of endocrine active chemicals: identifying chemicals of regulatory concern.
Bars R; Fegert I; Gross M; Lewis D; Weltje L; Weyers A; Wheeler JR; Galay-Burgos M
Regul Toxicol Pharmacol; 2012 Oct; 64(1):143-54. PubMed ID: 22735369
[TBL] [Abstract][Full Text] [Related]
5. Screening chemicals for thyroid-disrupting activity: A critical comparison of mammalian and amphibian models.
Pickford DB
Crit Rev Toxicol; 2010 Nov; 40(10):845-92. PubMed ID: 20684730
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment of 'endocrine substances': guidance on identifying endocrine disruptors.
Lewis RW
Toxicol Lett; 2013 Dec; 223(3):287-90. PubMed ID: 24036001
[TBL] [Abstract][Full Text] [Related]
7. The adrenal cortex and steroidogenesis as cellular and molecular targets for toxicity: critical omissions from regulatory endocrine disrupter screening strategies for human health?
Harvey PW; Everett DJ
J Appl Toxicol; 2003; 23(2):81-7. PubMed ID: 12666151
[TBL] [Abstract][Full Text] [Related]
8. Science based guidance for the assessment of endocrine disrupting properties of chemicals.
Bars R; Broeckaert F; Fegert I; Gross M; Hallmark N; Kedwards T; Lewis D; O'Hagan S; Panter GH; Weltje L; Weyers A; Wheeler JR; Galay-Burgos M
Regul Toxicol Pharmacol; 2011 Feb; 59(1):37-46. PubMed ID: 20858523
[TBL] [Abstract][Full Text] [Related]
9. Benefits of the maximum tolerated dose (MTD) and maximum tolerated concentration (MTC) concept in aquatic toxicology.
Hutchinson TH; Bögi C; Winter MJ; Owens JW
Aquat Toxicol; 2009 Feb; 91(3):197-202. PubMed ID: 19124163
[TBL] [Abstract][Full Text] [Related]
10. Environmental effect assessment for sexual endocrine-disrupting chemicals: Fish testing strategy.
Knacker T; Boettcher M; Frische T; Rufli H; Stolzenberg HC; Teigeler M; Zok S; Braunbeck T; Schäfers C
Integr Environ Assess Manag; 2010 Oct; 6(4):653-62. PubMed ID: 20872646
[TBL] [Abstract][Full Text] [Related]
11. Paraben esters: review of recent studies of endocrine toxicity, absorption, esterase and human exposure, and discussion of potential human health risks.
Darbre PD; Harvey PW
J Appl Toxicol; 2008 Jul; 28(5):561-78. PubMed ID: 18484575
[TBL] [Abstract][Full Text] [Related]
12. Implications of research on endocrine disruption for the environmental risk assessment, regulation and monitoring of chemicals in the European Union.
Matthiessen P; Johnson I
Environ Pollut; 2007 Mar; 146(1):9-18. PubMed ID: 16996184
[TBL] [Abstract][Full Text] [Related]
13. About hazard and risk assessment: regulatory approaches in assessing safety in the European Union chemicals legislation.
Gebel T; Lechtenberg-Auffarth E; Guhe C
Reprod Toxicol; 2009 Sep; 28(2):188-95. PubMed ID: 19631154
[TBL] [Abstract][Full Text] [Related]
14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
15. Adrenal toxicology: a strategy for assessment of functional toxicity to the adrenal cortex and steroidogenesis.
Harvey PW; Everett DJ; Springall CJ
J Appl Toxicol; 2007; 27(2):103-15. PubMed ID: 17265431
[TBL] [Abstract][Full Text] [Related]
16. Low dose mixture effects of endocrine disrupters: implications for risk assessment and epidemiology.
Kortenkamp A
Int J Androl; 2008 Apr; 31(2):233-40. PubMed ID: 18248400
[TBL] [Abstract][Full Text] [Related]
17. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
Lodén M; Ungerth L; Serup J
Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
[TBL] [Abstract][Full Text] [Related]
18. Alternative methods to safety studies in experimental animals: role in the risk assessment of chemicals under the new European Chemicals Legislation (REACH).
Lilienblum W; Dekant W; Foth H; Gebel T; Hengstler JG; Kahl R; Kramer PJ; Schweinfurth H; Wollin KM
Arch Toxicol; 2008 Apr; 82(4):211-36. PubMed ID: 18322675
[TBL] [Abstract][Full Text] [Related]
19. The European Union's REACH regulation: a review of its history and requirements.
Williams ES; Panko J; Paustenbach DJ
Crit Rev Toxicol; 2009; 39(7):553-75. PubMed ID: 19650717
[TBL] [Abstract][Full Text] [Related]
20. Assessing and managing risks arising from exposure to endocrine-active chemicals.
Phillips KP; Foster WG; Leiss W; Sahni V; Karyakina N; Turner MC; Kacew S; Krewski D
J Toxicol Environ Health B Crit Rev; 2008 Mar; 11(3-4):351-72. PubMed ID: 18368561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
